Variation of Orthokeratology Lens Treatment Zone (VOLTZ) Study

July 18, 2022 updated by: Pauline Cho, The Hong Kong Polytechnic University
This project aims to study the effects of treatment characteristics on myopia control in orthokeratology by investigating the effects of modified treatment zone by reducing the lens back optic zone diameter on the effect of myopia control. The project will be a two-year randomized, double-masked (examiner - mask axial length only) study conducted at The Hong Kong Polytechnic University recruiting sixty Chinese subjects aged between 6-11. Subjects will be randomly assigned to two ortho-k groups. The Control group will wear KATT BeFree lens with a BOZD of 6mm while the Test group will wear KATT MC lens with a modified BOZD of 5mm.

Study Overview

Status

Completed

Conditions

Detailed Description

Orthokeratology (Ortho-k) treatment reduces the degree of myopia of the eye by flattening the central cornea. This central flattened zone is referred to as the treatment zone (TZ). Munnerlyn's formula describes the negative correlation between refractive correction and treatment zone size given a maximum ablation depth limited by the patient's corneal thickness in refractive surgery. This implies smaller TZ for higher myopic reduction and, indeed, a study found marginally smaller TZ of 0.3mm in higher myopic group. In ortho-k, it has been speculated that TZ may be associated with the effect of the treatment. The TZ is defined as the central flattened area enclosed by points with zero power/curvature changes comparing to pre-treatment condition on various topography maps.

Previous studies determine the TZ characteristics based on different types of topographical subtractive maps including tangential, axial and refractive maps. A study compared TZ parameters derived from the three different maps. The study defined the TZ as the area enclosed by zero power change in different subtractive maps; 12 such points equally spaced 30 degree apart to construct a best-fit ellipse. Geometrical center of this ellipse was used to determine the TZ decentration and TZ diameter along vertical and horizontal axes. The study found significantly less TZ decentration and diameter in tangential map comparing to axial and refractive maps and no significant difference between the latter two. Based on these findings, the investigators suggested that either refractive or axial map would be of high validity and accuracy in determining TZ characteristics.

The current study would investigate the effect of TZ on myopic control in ortho-k. TZ, defined as the area enclosed by zero power change in subjective maps will be employed. The tangential and refractive subtractive maps will be used to determine the TZ. Characteristics of the TZ, including diameter, slope, depth, volume, would be analyzed based on topographical subtractive maps and the effect of each of these characteristics on myopia control will be evaluated. The role of pupil size during normal viewing condition (distance and near) will also be investigated.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Kowloon, Hong Kong
        • School of Optometry, The Hong Kong Polytechnic University
      • Kowloon, Hong Kong
        • School of Optometry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 11 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Manifest myopia between 1.00-4.00D in both eyes at screening visit
  • Manifest astigmatism ≤2.50D; with-the-rule astigmatism (axes 180 ± 30)

    • 2.50D; astigmatism with other axes ≤0.50D in both eyes at screening visit
  • <1.00D difference in manifest spherical equivalent (SE) between the two eyes at screening visit
  • Baseline cycloplegic objective refraction between 1.00-4.00D in sphere; astigmatism ≤2.50D; <1.00D difference in manifest SE between the two eyes
  • Best-corrected logMAR visual acuity 0.10 or better in both eyes Symmetrical corneal topography with corneal toricity <2.00D in either eye
  • Normal ocular health other than myopia
  • Agree to be randomized and to attend the scheduled visits and aftercare

Exclusion Criteria:

  • Contraindications to atropine: known allergies or cardiovascular disease, epilepsy
  • Contraindications to contact lens wear and ortho-k: corneal scar, history of ocular inflammation/infection, limbus-to-limbus corneal cylinder and dislocated corneal apex
  • Strabismus or amblyopia
  • History of myopia control treatment (e.g. soft contact lenses, progressive add spectacles, atropine eye drops)
  • Rigid contact lens (including ortho-k) wear experience
  • Systemic condition which might affect refractive development (for example, Down syndrome, Marfan's syndrome)
  • Ocular conditions which might affect refractive error (for example, cataract, ptosis)
  • Poor response to lens wear including poor lens handling, poor vision and/ocular response after lens modifications
  • Poor compliance with schedule visits

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Modified ortho-k lenses
Participants wearing ortho-k lens with a modified BOZD of 5mm
KETT MC lens
Active Comparator: Ortho-k lenses
Participants wearing ortho-k lens with a standardized BOZD of 6mm
KATT BeFree lens

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in axial length before and after two years of lens wear
Time Frame: 2 years
To determine the change in axial length measured at baseline and two years after lens wear using IOLMaster
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment zone characteristics
Time Frame: 2 years
Corneal topography will be determined by Medmont topographer and the treatment zone characteristics will be determined from the subtractive maps
2 years
Pupil sizes
Time Frame: 2 years
Photopic and mesotopic pupil sizes
2 years
Choroidal thickness
Time Frame: 2 years
Choroidal thickness measurement will be determined by both LenStar and posterior OCT
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2017

Primary Completion (Actual)

March 21, 2021

Study Completion (Actual)

July 27, 2021

Study Registration Dates

First Submitted

June 14, 2017

First Submitted That Met QC Criteria

June 16, 2017

First Posted (Actual)

June 19, 2017

Study Record Updates

Last Update Posted (Actual)

July 20, 2022

Last Update Submitted That Met QC Criteria

July 18, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HSEARS20170118004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myopia

Clinical Trials on Modified ortho-k lenses

Subscribe